Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Germany’s Affimed has signed a deal with Roche’s Genentech unit to develop cancer immunotherapies that activate natural killer cells, in a deal potentially worth more than $5 billion. The first wave ...